Top 5 Stocks to Buy Now
→ Your book attached (From Profits Run) (Ad)tc pixel Free AREC Stock Alerts

Arecor Therapeutics (AREC) Competitors

Arecor Therapeutics logo
GBX 62.90 +0.40 (+0.64%)
As of 08:34 AM Eastern
Compare

AREC vs. MPH, BVXP, FARN, 4BB, and ORPH

Should you buy Arecor Therapeutics stock or one of its competitors? MarketBeat compares Arecor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arecor Therapeutics include Mereo BioPharma Group plc (MPH.L) (MPH), Bioventix (BVXP), Faron Pharmaceuticals Oy (FARN), 4basebio (4BB), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.

How does Arecor Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Arecor Therapeutics has a net margin of 38.74% compared to Mereo BioPharma Group plc (MPH.L)'s net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Mereo BioPharma Group plc (MPH.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
Arecor Therapeutics 38.74%14.26%-37.31%

Mereo BioPharma Group plc (MPH.L) has higher earnings, but lower revenue than Arecor Therapeutics. Mereo BioPharma Group plc (MPH.L) is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
Arecor Therapeutics£1.71M13.86-£10.68M£2.0031.45

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
Arecor Therapeutics Neutral

6.0% of Arecor Therapeutics shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Arecor Therapeutics beats Mereo BioPharma Group plc (MPH.L) on 7 of the 8 factors compared between the two stocks.

How does Arecor Therapeutics compare to Bioventix?

Arecor Therapeutics (LON:AREC) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market.

6.0% of Arecor Therapeutics shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Bioventix had 2 more articles in the media than Arecor Therapeutics. MarketBeat recorded 2 mentions for Bioventix and 0 mentions for Arecor Therapeutics. Bioventix's average media sentiment score of 1.27 beat Arecor Therapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the news media.

Company Overall Sentiment
Arecor Therapeutics Neutral
Bioventix Positive

Bioventix has higher revenue and earnings than Arecor Therapeutics. Bioventix is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M13.86-£10.68M£2.0031.45
Bioventix£12.54M7.03£8.12M£140.5212.01

Bioventix has a net margin of 59.30% compared to Arecor Therapeutics' net margin of 38.74%. Bioventix's return on equity of 65.83% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Bioventix 59.30%65.83%54.07%

Summary

Bioventix beats Arecor Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Arecor Therapeutics compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Faron Pharmaceuticals Oy has a beta of 1.108, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Arecor Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market.

In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Arecor Therapeutics Neutral

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 6.0% of Arecor Therapeutics shares are held by institutional investors. 2.8% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 4.8% of Arecor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Arecor Therapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Arecor Therapeutics£1.71M13.86-£10.68M£2.0031.45

Arecor Therapeutics has a net margin of 38.74% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arecor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Arecor Therapeutics 38.74%14.26%-37.31%

Summary

Arecor Therapeutics beats Faron Pharmaceuticals Oy on 8 of the 10 factors compared between the two stocks.

How does Arecor Therapeutics compare to 4basebio?

4basebio (LON:4BB) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

In the previous week, 4basebio's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
4basebio Neutral
Arecor Therapeutics Neutral

4basebio currently has a consensus target price of GBX 1,400, indicating a potential upside of 154.55%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than Arecor Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arecor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

4basebio has higher earnings, but lower revenue than Arecor Therapeutics. 4basebio is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.69M50.31-£9.84M-£109.00N/A
Arecor Therapeutics£1.71M13.86-£10.68M£2.0031.45

4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 6.0% of Arecor Therapeutics shares are owned by institutional investors. 12.1% of 4basebio shares are owned by insiders. Comparatively, 4.8% of Arecor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arecor Therapeutics has a net margin of 38.74% compared to 4basebio's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
Arecor Therapeutics 38.74%14.26%-37.31%

Summary

4basebio and Arecor Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Arecor Therapeutics compare to Open Orphan?

Open Orphan (LON:ORPH) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

6.0% of Arecor Therapeutics shares are owned by institutional investors. 4.8% of Arecor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arecor Therapeutics has a net margin of 38.74% compared to Open Orphan's net margin of 0.00%. Arecor Therapeutics' return on equity of 14.26% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Open OrphanN/A N/A N/A
Arecor Therapeutics 38.74%14.26%-37.31%

In the previous week, Open Orphan's average media sentiment score of 0.00 equaled Arecor Therapeutics'average media sentiment score.

Company Overall Sentiment
Open Orphan Neutral
Arecor Therapeutics Neutral

Open Orphan has higher revenue and earnings than Arecor Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Open Orphan£34.71M0.00N/AN/AN/A
Arecor Therapeutics£1.71M13.86-£10.68M£2.0031.45

Summary

Arecor Therapeutics beats Open Orphan on 5 of the 7 factors compared between the two stocks.

Get Arecor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AREC vs. The Competition

Export
MetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£23.75M£496.94M£6.81B£2.77B
Dividend YieldN/A3.86%2.68%6.16%
P/E Ratio31.453.1825.78366.66
Price / Sales13.867,182.39554.3685,978.63
Price / Cash5.0713.1346.3327.87
Price / Book3.7988.5210.767.76
Net Income-£10.68M-£96.07M£3.57B£5.89B
7 Day Performance3.20%1.72%3.20%-0.71%
1 Month Performance-10.14%0.56%2.36%-1.20%
1 Year Performance49.76%71.64%33.28%65.93%

Arecor Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AREC
Arecor Therapeutics
N/AGBX 62.90
+0.6%		N/A+41.8%£23.75M£1.71M31.4510
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
BVXP
Bioventix
N/AGBX 1,700
+2.7%		N/A-36.4%£88.83M£12.54M12.1012
FARN
Faron Pharmaceuticals Oy
N/AGBX 42
-6.7%		N/A-78.5%£83.80MN/AN/A34
4BB
4basebio
N/AGBX 500
-4.8%		GBX 1,400
+180.0%		-49.7%£77.43M£1.69MN/A101

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AREC) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Elon Musk, Larry Fink & Brian Armstrong are ALL Piling into This
Elon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...
Brownstone Research | Sponsoredtc pixel